With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59702-31-7,1-Ethylpiperazine-2,3-dione,as a common compound, the synthetic route is as follows.
The compound (0.15 g) obtained in Reference Example 20, 1-ethylpiperazine-2,3-dione (75 mg), sodium hydride (14 mg) and N,N-dimethylformamide (1 ml) were stirred at room temperature for 1 hr. The reaction mixture was diluted with ethyl acetate (100 ml), washed with 5% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. 4N Hydrogen chloride-ethyl acetate solution (10 ml) was added to the residue, and the mixture was stirred at room temperature for 1 hr. The solvent was evaporated under reduced pressure, and the residue was washed with ethyl acetate to give the title compound (72 mg) as a colorless powder. melting point 264-271C. Elemental analysis (C15H22ClN3O2¡¤0.1H2O) Calcd.: C, 57.45; H, 7.13; N, 13.40. Found: C, 57.19; H, 7.03; N, 13.40., 59702-31-7
The synthetic route of 59702-31-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Takeda Pharmaceutical Company Limited; EP1876179; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics